SHYNDEC(SH:600420) Zhi Tong Cai Jing·2025-09-12 08:59Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420.SH), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a supplemental application regarding sodium bicarbonate injection, which includes an increase in specifications and has passed the consistency evaluation for generic drug quality and efficacy [1]. Group 1 - The sodium bicarbonate injection is classified as an antacid [1]. - Indications for sodium bicarbonate injection include: (1) treatment of metabolic acidosis; (2) prevention of uric acid kidney stones, reduction of nephrotoxicity from sulfonamides, and prevention of hemoglobin deposition in renal tubules during acute hemolysis; (3) intravenous infusion for non-specific treatment of certain drug poisonings, such as barbiturates, salicylates, and methanol [1].